Therapeutic Antibody

SAR428926 (anti-LAMP1) is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity.

SAR428926 (anti-LAMP1) is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity.

SAR428926 (anti-LAMP1) is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity.

U3-1565 (anti-HBEGF) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which

U3-1565 (anti-HBEGF) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which

U3-1565 (anti-HBEGF) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which

U3-1565 (anti-HBEGF) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which

Volagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).

Volagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).

Volagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).

Volagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).